Finanztrends
Deine Einschätzung
Was spricht für und gegen Advanced Proteome Therapeutics in den nächsten Jahren?
Pro
?
M****
?
U****************
?
M************
Kontra
?
W******* i* V********
?
L*********** I********** f** d** n******* J****
?
A****************
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von Advanced Proteome Therapeutics im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Northwest Biotherapeutics Inc. | 0,00 % | -12,16 % | -23,53 % | -38,68 % | -36,89 % | -73,25 % | -87,85 % |
| Larimar Therapeutics Inc. | -1,14 % | 4,82 % | 21,68 % | 9,43 % | 4,82 % | -4,40 % | -60,90 % |
| Achieve Life Sciences Inc. | 2,70 % | 7,55 % | 0,88 % | 157,34 % | 54,05 % | 15,85 % | -7,32 % |
News
Solventum Q2 Earnings Call Highlights
Key Points
- Interested in Solventum Corporation? Here are five stocks we like better.
- Second-quarter results exceeded expectations: Sales reached $2.2 billion, with organic growth of 9.5%, while
Smith & Nephew SNATS Q2 Earnings Call Highlights
Key Points
- Interested in Smith & Nephew SNATS, Inc.? Here are five stocks we like better.
- Smith & Nephew cut its 2026 underlying revenue-growth outlook to about 4% after second-quarter growth
Rayonier Advanced Materials Q2 Earnings Call Highlights
Key Points
- Interested in Rayonier Advanced Materials Inc.? Here are five stocks we like better.
- Strategic review remains active: CEO Dan Krawczyk said the process is progressing with urgency and